Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Immunotherapeutic approaches targeting prostate cancer and its microenvironment The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/immunotherapeutic-approaches-targeting-prostate-cancer-and-its-YaPmYL167D
Publisher
Springer Journals
Copyright
Copyright © 2012 by Springer-Verlag Wien
Subject
Medicine & Public Health; Medicine/Public Health, general; Oncology
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-012-0021-4
Publisher site
See Article on Publisher Site

Abstract

The high frequency of prostate cancer in the population of the industrial nations and the lack of curative therapies for advanced hormone refractory disease mandates the investigation of novel, more efficient therapeutic approaches. Recent advances in rodent models have evidenced the therapeutic effects of antiprostate cancer vaccines, T cell transfer strategies and blockade of the negative regulator of T cell activation CTLA-4. Besides, several immunotherapeutic products have already been investigated in later-phase clinical trials and shown clinical benefit while maintaining an excellent quality of life for the treated patients, in particular, when compared with chemotherapy. However, there is also evidence for a synergistic effect of conventional treatment strategies and immunological antitumor approaches. For example, thermal ablation which is applied to destroy tumor tissue may help to activate tumor-specific T cells by elevating the presentation of tumor antigens to the immune system. Based on the experimental and clinical data the role of immune-based therapies is likely to become more prominent in the future years. This review summarizes results from contemporary immunologic therapies and clinical trials against prostate cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jun 5, 2012

References

  • Cancer statistics 2010
    Jemal, A; Siegel, R; Xu, J
  • A history of prostate cancer treatment
    Denmeade, SR; Isaacs, JT
  • Early androgen deprivation for prostate cancer?
    Eisenberger, MA; Walsh, PC
  • Role of secondary hormonal therapy in the management of recurrent prostate cancer
    Ryan, CJ; Small, EJ
  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    Tannock, I; Osoba, D; Stockler, MR
  • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    Petrylak, DP; Tangen, CM; Hussain, MH
  • Present status and perspectives in the treatment of hormone-refractory prostate cancer
    Silvestris, N; Leone, B; Numico, G
  • The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer
    McArdle, PA; Canna, K; McMillan, DC
  • Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer
    Elkord, E; Rowbottom, AW; Kynaston, H
  • Augmentation of T cell levels and responses induced by androgen deprivation
    Roden, AC; Moser, MT; Tri, SD
  • CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
    Miller, AM; Lundberg, K; Ozenci, V
  • Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
    Sfanos, KS; Bruno, TC; Maris, CH
  • Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors
    Zheng, X; Gao, JX; Zhang, H
  • Altered immunity accompanies disease progression in a mouse model of prostate dysplasia
    Tien, AH; Xu, L; Helgason, CD
  • CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells
    Dürr, C; Pfeifer, D; Claus, R
  • Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer
    Schellhammer, PE; Hershberg, RM
  • Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines
    Michiels, A; Tuyaerts, S; Bonehill, A
  • Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma
    Jarnjak-Jankovic, S; Pettersen, RD; Saeboe-Larssen, S
  • Recognition of prostate-specific antigen peptide determinants by human CD4and CD8 T cells
    Corman, JM; Sercarz, EE; Nanda, NK
  • Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer
    Alexander, RB; Brady, F; Leffell, MS
  • In vitro generation of human cytotoxic Tlymphocytes specific for peptides derived from prostata-specific antigen
    Correale, P; Walmsley, K; Nieroda, C
  • Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
    Thomas-Kaskel, AK; Zeiser, R; Jochim, R
  • Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges
    Paller, CJ; Antonarakis, ES
  • Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
    Sims, RB
  • Increased CD8+ T cell function following castration and immunization is countered by parallel expansion of regulatory T cells
    Tang, S; Moore, ML; Grayson, JM
  • In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice
    Akins, EJ; Moore, ML; Tang, S
  • Testosterone replacement effectively inhibits the development of experimental autoimmune orchitis in rats: evidence for a direct role of testosterone on regulatory T cell expansion
    Fijak, M; Schneider, E; Klug, J
  • Neonatal castration affects in trathymic kinetics of T cell differentiation and the spleen T-cell level
    Radojevic, K; Arsenovic-Ranin, N; Kosec, D
  • Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
    Koh, YT; Gray, A; Higgins, SA
  • Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice
    Arredouani, MS; Tseng-Rogenski, SS; Hollenbeck, BK
  • Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    Drake, CG; Doody, AD; Mihalyo, MA
  • Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy
    Waitz, R; Solomon, SB; Petre, EN; Trumble, AE; Fassò, M; Norton, L
  • Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Eertwegh, AJ; Versluis, J; Berg, HP
  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Madan, RA; Mohebtash, M; Arlen, PM
  • Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
    Zhu, D; Corral, LG; Fleming, YW
  • Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
    Corral, LG; Haslett, PA; Muller, GW
  • Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
    Lentzsch, S; LeBlanc, R; Podar, K
  • Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study
    Keizman, D; Zahurak, M; Sinibaldi, V